A 16-year-old boy with severe gamma-butyrolactone (GBL) withdrawal delirium

Pharmacopsychiatry

Volumn 42, Issue 5, 2009, Pages 202-203

  Zepf, F D ^a,b,c   Holtmann, M ^c,d   Duketis, E ^c   Maier, J ^c   Radeloff, D ^c   Wagner, A ^c   Poustka, F ^c   Wockel L ^a,c  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b JARA TRANSLATIONAL BRAIN MEDICINE   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIAZEPAM; DOXYCYCLINE; ENOXAPARIN; GAMMA BUTYROLACTONE; HALOPERIDOL; INFUSION FLUID; LEVOMEPROMAZINE; LORAZEPAM; NEUROLEPTIC AGENT; NITRATE; PHENOBARBITAL; THIAMINE; CENTRAL NERVOUS SYSTEM AGENTS;

ADOLESCENT; ANAMNESIS; ATAXIA; BODY TEMPERATURE; CASE REPORT; CLINICAL FEATURE; DELIRIUM; DISEASE SEVERITY; DRUG WITHDRAWAL; DYSTONIA; HOSPITAL READMISSION; HUMAN; INTENSIVE CARE UNIT; LETTER; MALE; PRIORITY JOURNAL; PSYCHIATRIC DEPARTMENT; PSYCHOSIS; RESTLESSNESS; THROMBOPHLEBITIS; WITHDRAWAL SYNDROME; CHEMICALLY INDUCED DISORDER; TREATMENT OUTCOME;

4-BUTYROLACTONE; ADOLESCENT; CENTRAL NERVOUS SYSTEM AGENTS; DELIRIUM; HUMANS; MALE; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 70350449461     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0029-1224163     Document Type: Letter

References (14)

1. Bialer PA. Designer drugs in the general hospital. Psychiatr Clin North Am 2002 25 231-243
2. Dyer JE, Roth B, Hyma BA. Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med 2001 37 147-53
3. Herold AH, Sneed KB. Treatment of a young adult taking gamma-butyrolactone (GBL) in a primary care clinic. J Am Board Fam Pract 2002 15 161-163
4. Hohl-Radke F, Voß M, Staedt J. Severe delirium of uncertain origin in a German psychiatric unit caused by gamma-butyrolactone withdrawal. Pharmacopsychiatry 2008 41 200-201
5. Kam PC, Yoong FF. Gamma-hydroxybutyric acid: an emerging recreational drug. Anaesthesia 1998 53 1195-1198
6. McDaniel CH, Miotto KA. Gamma hydroxybutyrate (GHB) and gamma butyrolactone (GBL) withdrawal: five case studies. J Psychoactive Drugs 2001 33 143-149
7. McDonough M, Kennedy N, Glasper A, etal. Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend 2004 75 3-9
8. Miotto K, Roth B. GHB withdrawal syndrome Texas Commission on Alcohol and Drug Abuse (TCADA) March 2001
9. Nimmerrichter AA, Walter H, Gutierrez-Lobos KE, etal. Double-blind controlled trial of gamma-hydroxybutyrate and clomethiazole in the treatment of alcohol withdrawal. Alcohol Alcohol 2002 37 67-73
10. Rosenberg MH, Deerfield LJ, Baruch EM. Two cases of severe gamma-hydroxybutyrate withdrawal delirium on a psychiatric unit: recommendations for management. Am J Drug Alcohol Abuse 2003 29 487-496
11. Schneir AB, Ly BT, Clark RF. A case of withdrawal from the GHB precursors gamma-butyrolactone and 1,4-butanediol. J Emerg Med 2001 21 31-33
12. Tarabar AF, Nelson LS. The gamma-hydroxybutyrate withdrawal syndrome. Toxicol Rev 2004 23 45-49
13. Wojtowicz JM, Yarema MC, Wax PM. Withdrawal from gamma-hydroxybutyrate,1, 4-butanediol and gamma-butyrolactone: a case report and systematic review. Can J Emergency Med 2008 10 69-74
14. Zepf FD, Holtmann M, Duketis E, etal. Entzugsdelir nach Missbrauch von GHB-(Gamma-Hydroxybutyrat) und seiner Vorstufen Grundlagen und Bedeutung für die Kinder- und Jugendpsychiatrie. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie. 2009 37 (5) 413-420